Minocycline
Amzeeq, Arestin, Minocin, Minolira, Solodyn, Ximino, Zilxi (minocycline) is a small molecule pharmaceutical. Minocycline was first approved as Minocin on 1982-01-01. It is used to treat acne vulgaris, anthrax, borrelia infections, chancroid, and cholera amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
infections | D007239 |
respiratory tract diseases | D012140 |
eye diseases | D005128 |
urogenital diseases | D000091642 |
skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Amzeeq, Arestin, Minocin, Minolira, Solodyn, Ximino, Zilxi (generic drugs available since 1990-07-31)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Minocycline hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MINOCIN | Bausch Health Companies | N-050649 RX | 1990-05-31 | 2 products, RLD |
SOLODYN | Bausch Health Companies | N-050808 RX | 2009-07-23 | 5 products, RLD, RS |
MINOLIRA | Novan | N-209269 RX | 2017-05-08 | 2 products, RS |
XIMINO | Journey Medical | N-201922 RX | 2012-07-11 | 3 products |
AMZEEQ | Journey Medical | N-212379 RX | 2019-10-18 | 1 products, RLD, RS |
ZILXI | Journey Medical | N-213690 RX | 2020-05-28 | 1 products, RLD, RS |
ARESTIN | Orapharma | N-050781 RX | 2001-02-16 | 1 products, RLD, RS |
MINOCIN | REMPEX | N-050444 RX | 1982-01-01 | 1 products, RLD, RS |
Show 6 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
amzeeq | New Drug Application | 2023-01-25 |
arestin | New Drug Application | 2020-06-01 |
dynacin | ANDA | 2014-12-18 |
minocin | New Drug Application | 2021-03-18 |
minocycline hydrochloride | ANDA | 2023-06-19 |
minolira extended release | New Drug Application | 2019-09-04 |
solodyn | New Drug Application | 2017-09-12 |
ximino | New Drug Application | 2021-01-18 |
zilxi | New Drug Application | 2022-09-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
acne vulgaris | EFO_0003894 | D000152 | L70 |
anthrax | — | D000881 | A22 |
borrelia infections | EFO_1000842 | D001899 | — |
chancroid | — | D002602 | A57 |
cholera | — | D002771 | A00 |
escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
meningococcal infections | EFO_0004249 | D008589 | A39 |
mycoplasma infections | — | D009175 | — |
plague | EFO_0007481 | D010930 | A20 |
psittacosis | EFO_0007410 | D009956 | A70 |
Show 4 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Minocycline Hydrochloride, Amzeeq, Journey | |||
10398641 | 2037-09-08 | U-2647 | |
10849847 | 2037-09-08 | U-2647 | |
8865139 | 2030-10-01 | DP | U-1631, U-2647 |
8945516 | 2030-10-01 | DP | |
8992896 | 2030-10-01 | DP | U-1631, U-2647 |
9675700 | 2030-10-01 | DP | U-1631, U-2647 |
10086080 | 2030-10-01 | U-2647 | |
10137200 | 2030-10-01 | U-2647 | |
10213512 | 2030-10-01 | DP | U-1631, U-2647 |
10265404 | 2030-10-01 | DP | |
10517882 | 2030-10-01 | U-2647 | |
10821187 | 2030-10-01 | U-2647 | |
Minocycline Hydrochloride, Minolira, Epi Hlth | |||
11103517 | 2036-04-07 | DP | |
Minocycline Hydrochloride, Solodyn, Bausch | |||
9192615 | 2031-11-17 | DP | |
7541347 | 2027-04-02 | U-917 | |
7544373 | 2027-04-02 | DP | |
7919483 | 2027-03-07 | U-124, U-1078 | |
7790705 | 2025-06-24 | U-124, U-1078 | |
8252776 | 2025-06-24 | U-124 | |
8268804 | 2025-06-24 | U-124, U-1078 | |
8722650 | 2025-06-24 | U-1078 | |
Minocycline Hydrochloride, Minocin, Rempex | |||
9084802 | 2031-05-12 | U-282 | |
9278105 | 2031-05-12 | U-282 | |
Minocycline Hydrochloride, Zilxi, Journey | |||
10322186 | 2030-10-01 | U-1631 | |
10946101 | 2030-10-01 | U-1631 |
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AB: Antiinfectives and antiseptics for local oral treatment
— A01AB23: Minocycline
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AF: Antiinfectives for treatment of acne
— D10AF07: Minocycline
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01A: Tetracycline antibiotics
— J01AA: Tetracyclines
— J01AA08: Minocycline
HCPCS
Code | Description |
---|---|
J2265 | Injection, minocycline hydrochloride, 1 mg |
Clinical
Clinical Trials
43 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 2 | 3 | 1 | 1 | 1 | 7 |
Low cardiac output | D002303 | 1 | 2 | 2 | 1 | 1 | 6 | ||
Cardiogenic shock | D012770 | R57.0 | 1 | — | — | 2 | — | 3 | |
Septic shock | D012772 | A48.3 | — | 1 | — | 1 | — | 2 | |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | 1 | — | — | 1 | — | 2 |
Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | 1 | — | 1 | |
Pulmonary edema | D011654 | EFO_1001134 | J81 | — | — | — | 1 | — | 1 |
Hemodynamics | D006439 | — | — | — | 1 | — | 1 | ||
Anesthesia | D000758 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiac surgical procedures | D006348 | — | — | 1 | — | — | 1 | ||
Mitral valve insufficiency | D008944 | HP_0001653 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart failure | D006333 | EFO_0003144 | I50 | 4 | 3 | — | — | 1 | 6 |
Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | 3 | — | — | — | 3 |
Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | 1 | — | — | 1 | 2 |
Persistent fetal circulation syndrome | D010547 | EFO_1001103 | P29.3 | — | 1 | — | — | 1 | 2 |
Intracranial vasospasm | D020301 | EFO_1000994 | G45.9 | — | 1 | — | — | 1 | 2 |
Right ventricular dysfunction | D018497 | 1 | 1 | — | — | — | 2 | ||
Cardio-renal syndrome | D059347 | — | 1 | — | — | — | 1 | ||
Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | — | — | — | 1 |
Heart transplantation | D016027 | EFO_0010673 | — | 1 | — | — | — | 1 | |
Myocardial reperfusion injury | D015428 | EFO_0002687 | 1 | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | — | 1 | 1 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 1 | 1 |
Aortic valve stenosis | D001024 | EFO_0000266 | Q25.1 | — | — | — | — | 1 | 1 |
Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | — | — | — | 1 | 1 |
Physiologic monitoring | D008991 | — | — | — | — | 1 | 1 | ||
Hepatectomy | D006498 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | MINOCYCLINE |
INN | minocycline |
Description | Minocycline zwitterion is a zwitterion obtained by transfer of a proton from the 2-hydroxy group to the 1-amino group of minocycline. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.). It is a zwitterion and an a tetracycline zwitterion. It is a conjugate acid of a minocycline(1-). It is a tautomer of a minocycline. |
Classification | Small molecule |
Drug class | antibiotics (tetracycline derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O |
Identifiers
PDB | — |
CAS-ID | 10118-90-8 |
RxCUI | 6980 |
ChEMBL ID | CHEMBL1434 |
ChEBI ID | 50694 |
PubChem CID | 51537604 |
DrugBank | DB01017 |
UNII ID | FYY3R43WGO (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Amzeeq - Fortress Biotech, Inc.
$
€
£
₣

Mock data
Subscribe for the real data
Subscribe for the real data

Mock data
Subscribe for the real data
Subscribe for the real data
Minolira - Novan
$
€
£
₣

Mock data
Subscribe for the real data
Subscribe for the real data

Mock data
Subscribe for the real data
Subscribe for the real data
Minocin - MELINTA THERAPEUTICS, INC. /NEW/
$
€
£
₣

Mock data
Subscribe for the real data
Subscribe for the real data

Mock data
Subscribe for the real data
Subscribe for the real data
Ximino - Fortress Biotech, Inc.
$
€
£
₣

Mock data
Subscribe for the real data
Subscribe for the real data

Mock data
Subscribe for the real data
Subscribe for the real data
Ximino - Journey Medical
$
€
£
₣

Mock data
Subscribe for the real data
Subscribe for the real data

Mock data
Subscribe for the real data
Subscribe for the real data
Zilxi - Fortress Biotech, Inc.
$
€
£
₣

Mock data
Subscribe for the real data
Subscribe for the real data

Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 28,293 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
545 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more